Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Индивидуальный выбор гормонального контрацептивного средства

https://doi.org/10.33667/2078-5631-2019-1-1(376)-6-14

Полный текст:

Аннотация

Контрацепция является уникальным средством, помогающим не только избежать нежеланной беременности и ее прерывания, но и получить дополнительную пользу для здоровья. Однако распространенность применения противозачаточных средств в целом и самой ресурсной, с позиций дополнительных преимуществ, гормональной контрацепции далеко не соответствует реальным потребностям. В представленном обзоре обосновывается алгоритм индивидуального подбора гормонального препарата в зависимости от клинического портрета женщины с целью решения задачи надежного и безопасного предохранения от беременности с профилактическими и лечебными эффектами.

Об авторе

И. В. Кузнецова
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России
Россия


Список литературы

1. Veljkovic M, Veljkovic S. The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users. MedPregl. 2010; 63 (9-10): 657-661.

2. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010; 127 (2): 442-151.

3. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010; 82 (3): 221-229.

4. Прилепская В. Н., Тарасова М. А., Назарова Н. М., Летуновская А. Б. Международный проект “CHOICE": краткий обзор результатов исследования. Гинекология. 2010; 12 (4): 26-28.

5. Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013; 11 (1): 41-47.

6. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013; 27 (1): 13-24.

7. Dhont M, Verhaeghe V. Hormonal anticonception anno2013: a clinician’s view. FVVin ObGyn 2013; 5 (2): 149-159.

8. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016; 353: 02002.

9. Quist-Paulsen P, Nœss IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, Hammerstr0m J. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT2). Haematologica. 2010; 95 (1): 119-125.

10. Mayeda ER, Torgal AH, Westhoff CL. Weight and Body Composition Changes During Oral Contraceptive Use in Obese and Normal Weight Women. J Womens Health (Larchmt) 2014; 23 (1): 38-t3.

11. Blum RW, Astone NM, Decker MR, et al. A conceptual framework for early adolescence: A platform for research. Int J Adolesc Med Health 2014; 26: 321e31.

12. Anttila L, Bachmann G, Hernadi L, et al. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 yg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur Obstet Gynecol Reprod Biol. 2011; 155 (2): 180-182.

13. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. Products information updated to help women make informed decision about their choice of contraception. European Medicines Agency. 2014:4p.

14. Havrilesky LJ, Gierisch JM, Moorman PG, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep). 2013; 212: 514.

15. Lidegaard 0, L0kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012; 366 (24): 2257-2266.

16. Yang L, Kuper H, Sandin S, et al. Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke. 2009; 40 (4): 1050-1058.

17. Virkus RA, L0kkegaard EC, Bergholt T, Mogensen U, Langhoff-Roos J, Lidegaard 0. Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study. Thromb Haemost. 2011; 106 (2): 304-309.

18. Bitzer J, Amy JJ, Beerthuizen R, et al. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur J Contracept Reprod Health Care. 2013; 18 (3): 143-147.

19. Lidegaard Ø, L0kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339: b2890.

20. Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December2009. J Fam Plann Reprod Health Care. 2010; 36: 117-122.

21. Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: A review of two recently published studies. J Fam Plann Reprod Health Care. 2010; 36: 33-38.

22. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. Br Med J. 2013; 347: f5298.

23. Szarewski A, Mansour D, Shulman LP. 50 years of ‘The Pill’: Celebrating a golden anniversary. J Fam Plann Reprod Health Care. 2010; 36:231-238.

24. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case-control study. BMJ. 2009; 339: b2921.

25. Арефьева М. Тромботический риск при использовании гормональных контрацептивов. Медицинские аспекты здоровья женщины. 2013; 5 (69): 66-70.

26. Ágren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17ß-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J ContraceptReprod Health Care. 2011; 16:444-457.

27. Winkler UH, Röhm P, Höschen K. An openlabel, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. Contraception. 2010; 81: 391-400.

28. Martinez F, Ramirez I, Perez-Campos E, et al. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2012; 17: 7-29.

29. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139.

30. EMA/607314/2013. PRAC confirms that benefits of all combined hormonal contraceptives (CHCs) continue to outweigh risks. 11. October 2013. http://www.ema.europa.eu.

31. Sehovic N, Smith KP. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Ann Pharmacother 2010; 44: 898-903.

32. Kerscher M, Reuther T, Krueger N, Buntrock H. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J Eur Acad Dermatol Venereol. 2013; 27 (5): 601^08.

33. Franceschini SA, Vieira CS, Martins WP, et al. Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium. Contraception 2013; 87: 766-72.

34. Bäckström T, Haage D, Löfgren M, Johansson IM, et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011; 191: 46-54.

35. Rothman KJ, Wise LA, S0rensen HT, Riis AH, Mikkelsen EM, Hatch EE. Volitional Determinants and Age-related Decline in Fecundability: A General Population Prospective Cohort Study in Denmark. FertilSteril. 2013; 99 (7): 1958-1964.

36. Allali F, Mansouri L, Abourazzak F, et al. The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women. BMC Women’s Health. 2009; 9:31.

37. Allen RH, Cwiak CA. Contraception for midlife women. Menopause 2016; 23 (1): 183-191.

38. Bonafede MM, MillerJD, Lukes AS et al. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. Clinin Econom Outcom Res. 2014:6423-429.

39. Reid RL, Fortier MP, Smith L, et al. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinylestradiol20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010; 82: 497-502.

40. Che Y, Liu X, Zhang B, Cheng L. Oral contraception following abortion: A systematic review and meta-analysis. Medicine (Baltimore). 2016; 95 (27): e3825.

41. Унанян А.Л., Аракелов С.Э., Полонская Л. С., и др. Постабортная реабилитация: теоретические и практические аспекты. Медицинский совет. 2014; 9:26-29.

42. Mueck AO. Dienogest: an oral progestogen for the treatment of endometriosis. Expert Rev Obstet Gynecol. 2011; 6 (1): 5-15.

43. Прилепская ВН, Тагиева АВ, Межевитинова ЕА. Внутриматочная контрацепция. М.: ГЭОТАР-Медиа, 2010; 176с.

44. James AH. Pregnancy-associated thrombosis. Hematology. 2009; 1:277-285.

45. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep. 2010 (RR-12); 59: 1-110.

46. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 14: e4944.

47. Hall KS, Trussell J, Schwarz EB. Progestin-only contraceptive pill use among women in the United States. Contraception. 2012; 86 (6): 653-658.

48. Practice Bulletin. Noncontraceptive Uses of Hormonal Contraceptives. Obstet Gynecol. 2010; 15 (1): 206-218.

49. Sitruk-Ware R, Nath A, Mishell DR. Contraception technology: past, present and future. Contraception. 2013; 87 (3): 319-330.

50. ACOG Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol. 2013; 122: 176-185.

51. ACOG. Management of acute abnormal uterine bleeding in non-pregnant women. Committee Opinion № 557. Obstet Gynecol. 2013; 121: 891-896.

52. Munro MG, et al, for the FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Intern J Gynecol Obstet. 2011; 113: 3-13.

53. SOGC. Abnormal Uterine Bleeding in Pre-Menopausal Women. 2013; 35 (5): 1-28.

54. Хурасева А. Б. Обоснование лечебно-профилактических мероприятий, направленных на профилактику рецидивов маточных кровотечений пубертатного периода. Педиатр. 2011; 11 (4): 43-50.

55. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016; 27 (1): e8.

56. Унанян А.Л., Сидорова И. С., Бабурин Д. В., Коссович Ю.М. Гиперпластические процессы эндометрия: вопросы патогенетической терапии. Гинекология. 2013; 15 (5): 32-35.

57. Карахалис Л. Ю., Федорович О. К., Басина И. Б., Червонная И. Ю. Влияние патогенетически обоснованной терапии аденомиоза на его течение. Эффективная фармакотерапия. 2009; 5: 18-24.

58. Toxqui L, Perez-Granados AM, Blanco-Rojo R, et al. A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and gynecological parameters in young women. BMC Women’s Health. 2014; 14: 71.

59. Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22 (11): 1931-1943.

60. Caruso S, Iraci M, Cianci S, et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest / 30 pg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 8: 923-931.

61. Тихомиров А.Л., Леденкова А. А. Актуальность применения комбинированных оральных контрацептивов в пролонгированном режиме. Акушерство, гинекология и репродукция. 2012; 6 (3): 18-22.

62. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - part 1. Endocr Pract. 2015; 21 (11): 1291-1300.

63. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012; 7: CD 004425.

64. Рагимова З. Э., Каиль-Горячкина М. В. Междисциплинарные аспекты андроген-зависимой дермопатии (обзор литературы). Consilium Medicum. Дерматология (прил.) 2016; 3: 56-62.

65. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013; 31: 4188-4198.

66. Brown J, O’Brien PMS, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD 001396.

67. Bitzer J, Paoletti AM. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin Drug Invest. 2009; 29 (2): 73-78.

68. Breech LL, Braverman PK. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int J Womens Health. 2009; 1: 85-95.

69. Геворкян М. А., Манухина Е. И., Смирнова С. О., Кузнецова Е. М. Профилактика формирования функциональных кист (клиническая лекция). Эффективная фармакотерапия. 2015; 5: 32-37.


Для цитирования:


Кузнецова И.В. Индивидуальный выбор гормонального контрацептивного средства. Медицинский алфавит. 2019;1(1):6-14. https://doi.org/10.33667/2078-5631-2019-1-1(376)-6-14

For citation:


Kuznetsova I.V. Individual choice of hormonal contraceptive. Medical alphabet. 2019;1(1):6-14. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-1(376)-6-14

Просмотров: 253


ISSN 2078-5631 (Print)